'"Plan to drive material increases in shareholder value in the next 3-5 years."
Don't believe it's at all damaging to say the above , it doesn't mean they're going to wait for 3 years before planning to create material value, they're starting now and plan to have created a material increase in shareholder value by 3-5 years , not from 3-5 years.
I think not.
Extract from todays Times MArket report.
Among the smaller stocks, Mereo Biopharma, a pharmaceuticals company that focuses on developing treatments for patients with rare diseases, rose by more than 7 per cent after Cantor Fitzgerald issued a “buy” rating on the stock and a target price of 720p, citing the value-adding potential of its respiratory therapies. The shares closed up 3p, or 7.1 per cent, at 45½p.
Need to correct that "Shareholders were promised NXP001 payments by end June"
That's simply not true.
In the RNS of 30th May it said "with remaining milestone payments expected during June 2019)"
Expected and promised are completely different things.
IMO it was unwise to use the word 'expected' in an RNS as in time this gets put to one side and becomes a 'promised' date.
Hopefully NFX will learn from this and be more careful in their wording of RNSes in the future.
Better to under promise and over deliver or in fact better not to promise at all.
Worth noting that the first NXP001 milestone payment was triggered and RNSed on 14th Sept 2018.
The receipt of this milestone payment was RNSed on Nov 27th 2018.
A time lapse between triggering and payment of c 2.5 months.
Because there was no 'expected' date of the receipt of that payment mentioned , there was no rumblings about the lateness of the payment!
Pretty negative article in today's Sunday Times
Peter Long’s struggle to save Countrywide
The travel trade veteran faces an uphill task to rescue our biggest estate agency chain
Numis analyst Chris Millington believes Long’s changes will fail to halt the decline, which in turn will force Countrywide to renegotiate with lenders, launch another cash call or sell some of its brands — or face breaching banking covenants by the end of next year.
“It feels like intensive care,” Millington said. “Regardless of who is at the helm, it feels like the rot has set in.”
Regulatory Affairs Consultant
Salary/Rate£60 - £80/hour
LocationM15, Manchester, Greater Manchester
Posted 26/07/2019 (10:33) Just Added
CompanyYourgene Health Description
Due to the recent growth of Yourgene Health we are looking for a Regulatory Affairs Consultant to join our Quality and Regulatory department on a 6 month contract. This role will provide effective management of the company’s regulatory affairs strategy, in order to support and fulfil the company’s global commercial strategy. The role requires management and liaison with internal team functions, regulatory authorities, and partner organisations. Minimum qualifications are a degree in Life Sciences, either in genetics or molecular biology and significant experience working within a regulatory affairs arena. The role will require the management of a team of regulatory professionals.
ESSENTIAL DUTIES AND RESPONSIBILITIES
Ovoca Bio plc (LSE: OVB; ISE: OVXA) announces that Yuri Radchenko, a Non-Executive Director of the Company, has notified the board of his intention to step down with immediate effect due to personal circumstances.
As per the website he currently holds 14.29% (11,656,202) shares.
Snack sales on a high in US states where cannabis legal
Snack manufacturers are enjoying a boost in sales in American states that have decriminalised marijuana.
The four-year compound annual growth rate of snack sales in these ten states is 7.2 per cent, compared with 6 per cent where cannabis remains illegal, a report by the market research company Nielsen found. The same rate of growth for confectionery is 2 per cent in decriminalised states and 1.3 per cent in illegal states.
Nielsen concluded that decriminalisation of the drug “presents big opportunities for the American food and beverage market, particularly for the snack and confectionery category”.
An academic study published this year appears to support the findings.
On average, sales of crisps rose by 5.3 per cent, cookies by 4.1 per cent and ice cream 3.1 per cent in Colorado, Oregon and Washington after the states decriminalised marijuana.
Scientific research suggests that tetrahydrocannabinol, the psychoactive ingredient in marijuana, releases a hormone that triggers hunger pangs and a neurotransmitter that increases appetite, which is nicknamed “the munchies”. Tetrahydrocannabinol also appears to enhance the smell and taste of food.
Coca-Cola and other large food and drink companies are experimenting with adding cannabidiol, a non-psychoactive constituent of cannabis thought to have calming and pain-relieving properties, to their products.
This market could be worth $16 billion by 2025, according to a recent estimate by Cowen, an investment bank.
Recreational use of cannabis remains a federal offence and the drug is grouped in the same category of illegal substances as heroin and cocaine. However, the law is not enforced, leaving states to set their own rules.
As the Group grows we are announcing fewer deals to the stockmarket as the threshold for meeting commerciality becomes proportionally higher, but I am delighted to report that we continue to win new customers in all major regions supporting the +45% revenue growth that we have reported in the last 12 months.
Cannabis benefits mount up for Cambridge science
Published: 16:34, 27 June 2019
With cannabis now legally available in the UK for medical use, applications are being investigated, so it is timely that Cambridge is hosting a two-part conference on the topic.
The two-part pilot, at The Old Divinity School – on July 7 and August 4 – will see the topic of medical cannabis discussed for the first time in Cambridge.
Organised by CANNTalks – ‘Curating A New Normal’ refers directly to the changes in cannabis reform happening globally – the events are titled ‘Live Talks: A Conversation on Cannabis’. The founders are a collective of scientists, academics, artists, activist disruptors, and influencers.
They describe the occasion as “a deep-dive into the science of the deepest parts of the plant-human relationship, illuminating on the complexities of the plant herself, before moving towards the regulatory changes; as well as exploring the philosophy and the ethics that have been behind prohibition for the last 90 years”.
One of those attending will be Dan Gooding, CEO of Nuformix, the Science Park-based pharmaceutical development company which uses cocrystal technology to unlock therapeutic potential of approved drugs in oncology supportive care and fibrosis.
“The event in Cambridge is very international,” Dan says. “It’s bringing together academics, patients, parents of patients – such as children with epilepsy – and regulators, and there’s a comprehensive list of topics about what’s going on and giving it airtime. We’ll be there!”
There is a heightened interest because Nuformix recently signed an agreement with Canadian firm Ebers Tech Inc. Ebers is “backed by leaders from the financial sector focused on the development of superior, differentiated cannabinoid products for a multitude of consumer product and therapeutic applications”.
The agreement – which saw Nuformix’s share price jump 30 per cent – is for the development, licensing and commercialisation of cannabinoid therapeutics and involves “up to £51million of upfront R&D and milestone payments, plus long-term royalties of 20 per cent of net sales medical cannabis”. It includes an upfront payment, with early-stage milestone payments expected this year.
So what’s the fuss about? Well, cannabis is entirely legal in Canada so there’s a healthy market to work with. The market in the US has also opened up to medical cannabis and that’s created interest in the UK.
GW Pharmaceuticals in Histon is already a global leader in developing cannabinoid-based medicines.
First off the block is cannabidiol, or CBD, which is an active ingredient in cannabis derived from the hemp plant – and it should be pointed out that this form of medical cannabis has zero THC, or tetrahydrocannabinol, which is the ingredient that gives “weed” its psychoactive effects.
China biotech groups spend billions on overseas drug candidates
US and European pharma groups benefit from cash-rich Chinese sector seeking new medicines
link to full article